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to the LM coronary artery, TAVR plus LM PCI is safe and technically
feasible, with short- and intermediate-term clinical outcomes com-
parable to patients undergoing TAVR alone. Our results suggest that
TAVR plus LM PCI is a reasonable option for patients who are at high
risk for surgery.
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BACKGROUND The size of the transcatheter heart valves (THV) is
overestimated up to 20% based on aortic annulus diameter measured
using computed tomography (CT). However, the prosthesis may not
be fully expanded during implantation. THV underexpansion might
have detrimental clinical consequences. The aim of this study was to
deﬁne the degree of underexpansion degree of different THVs,
introduced as the shrinking index, and its predicting role in pace-
maker implantation after transcatheter aortic valve implantation
(TAVI).
METHODS We enrolled 112 patients (68 men, 798 years old) who
underwent TAVI with the self-expanding CoreValve (n¼28), me-
chanically expanded Lotus valve (n¼ 35) or balloon expandable
Edwards SAPIEN XT (n¼18) and Edwards SAPIEN 3 (n¼ 31). The cover
index of the THV was calculated as the percentage difference of the
nominal prosthesis size and annulus diameter measured using CT.
Intraprocedural transesophageal echocardiography (TEE) was per-
formed to determine the size of the THV inﬂow after implantation.
The shrinking index was calculated as the percentage of the difference
between the inﬂow size by TEE and the nominal prosthesis size
divided by prosthesis size. After excluding the patients with baseline
pacemaker (n¼7) and patients deceased within 24 hours after TAVI
(n¼4), the role of the shrinking index for pacemaker implantation
within 30 days was investigated.
RESULTS Cover index per CT assessment was 187% for CoreValve,
24% for Lotus, 95% for Edwards SAPIEN and 45% for Edwards
SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁcantly larger than
the others). Compared with aortic annulus diameter measured using
TEE in long axis view, the overestimation increased to 289% for
CoreValve, 128% for Lotus, 1812% for Edwards SAPIEN and 128%
for Edwards SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁcantly
larger than the others). Conversely, the shrinking index after TAVI
was -306% for CoreValve, -205% for Lotus, -226% for SAPIEN XT
and -195% for SAPIEN 3 (ANOVA p<0.001, Corevalve was signiﬁ-
cantly larger than the others). The interobserver variability (relative
difference) of TEE in measuring the aortic annulus and prosthesis
inﬂow was 65% and 75% respectively. Using a cut-off value of -22%
of the shrinking index, the pacemaker implantation rate was of
borderline difference between patients with shrinking index lower
than -22% (pacemaker implantation rate 65%) and those higher than
-22% (35%) (univariate analysis p¼0.06). However, there was no sig-
niﬁcant difference within each type of THV.
CONCLUSIONS The shrinking index determines the degree of THV
underexpansion after TAVI and can be reliably measured with TEE.
The self-expanding CoreValve tended to be under-expanded the
most, indicated by the largest shrinking index. THV with a shrinking
index larger than 22% tended to predict higher pacemaker implanta-
tion rate after TAVI. Its deﬁnite predicting role needs further study
with larger patient population and more covariables included.
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BACKGROUND Mutidetector cardiac computed tomography (MDCT)
is the gold standard for aortic annular sizing in transcatheter aortic
valve replacement (TAVR). Balloon sizing is increasingly used in pa-
tients when there remains a discrepancy in preoperative assessment
for the most appropriate valve size that should be utilized. A com-
parison between balloon and MDCT sizing has not been reported.
METHODS We retrospectively reviewed 205 patients undergoing
balloon-expandable TAVR who underwent preoperative annular
MDCT or intraoperative balloon sizing. Baseline characteristics and
30-day outcomes are compared between groups. Logistic regression
modules were used to compare paravalvular leak (PVL) rates adjusting
for access site (TF or non-TF), valve type (SAPIEN or SAPIEN XT), size
(23, 26, or 29), and valve calciﬁcation.
RESULTS 205 patients underwent TAVR with MDCT (n¼110) or
balloon sizing (n¼95). Balloon sized patients were older (83 vs. 81
years, p¼0.03), with more valve calciﬁcation (60.2% vs. 30.9%,
p<0.001), and underwent more minimalist TAVR (61.1% vs. 40%,
p¼0.03). Balloon-sized patients also received less 29 mm valves (9.5%
vs. 29.1%, p¼0.001) and more intraprocedural balloon valvuloplasties
(2 vs. 1, p¼0.001), ﬂuoroscopy time (25.6 vs. 20.3 min, p¼0.001), and
intra-procedural contrast (130.0 vs. 108 mL, p¼0.01). Though we
found no difference between balloon and MDCT sizing in rates of
acute renal failure, annular rupture, and  mild PVL by angiography
or 30-day TTE; balloon sized patients had a higher aortic regurgitation
index (Table 1). 30-day rates of  moderate PVL were 7.0% with
balloon and 5.7% with MDCT sizing (p¼0.34). Balloon sizing recom-
mended a different valve size in 34% patients that underwent both
sizing methods (n¼50).
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(N[205)Balloon sized
(N: 95)MDCT sized
(N: 110) P-valueComposite
sizing-
complication,
N (%)29 (14.1) 14 (14.7) 15 (13.9) 0.82Post BAV
instability, N
(%)2 (1.0) 2 (2.1) 0 (0.0) 0.21Major vascular
complication,
N (%)7 (3.4) 1 (1.1) 6 (5.5) 0.13Tamponade, N
(%)4 (2.0) 2 (2.1) 2 (1.8) 1.0Annular rupture,
N (%)3 (1.5) 1 (1.1) 2 (1.8) 1.0Heart block
requiring new
ppm, N (%)14 (6.8) 7 (7.4) 7 (6.4) 0.78Postoperative
acute renal
failure, N (%)4 (2.0) 3 (3.2) 1 (0.9) 0.34Minor stroke, N
(%)1 (1.1) 0 (0.0) 1 (0.9) 1.0Major stroke, N
(%)1 (1.1) 0 (0.0) 1 (0.9) 1.030-Day
Readmissions,
N (%)13 (6.3) 6 (6.3) 7 (6.4) 1.030-day
Mortality, N
(%)3 (1.5) 1 (1.1) 2 (1.8) 1.0Angiography
paravalvular
leak, N (%)0.57*None 128 (62.4) 57 (60.0) 71 (64.5)Mild or greater 77 (37.6) 38 (40.0) 39 (35.5)Aortic
regurgitation
index, N (%)0.01*<25 68 (36.2) 23 (25.6) 45 (45.9)25 120 (53.8) 67 (74.4) 53 (54.1)
30-day
paravalvular
leak, N (%)0.78*None 129 (65.5) 54 (59.3) 75 (70.8)Mild or greater 68 (34.5) 37 (40.7) 31 (29.3)BAV ¼ Balloon Aortic Valvuloplasty, CPR ¼ cardiopulmonary resuscitation, ppm ¼ permanent pace-
maker.*Adjusted for valve type, size, access and aortic valve calciﬁcation
CONCLUSIONS In those patients in which optimal valve size remains
questionable, intraoperative balloon sizing is a safe procedure that
complements MDCT for annular sizing prior to TAVR.
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BACKGROUND Screening for internal carotid artery stenosis (ICAS)
with Doppler ultrasound is commonly used before cardiac surgery.
However, the relationship between ICAS and procedure-related stroke
in aortic valve replacement is unclear.METHODS We retrospectively reviewed patients with severe AS who
underwent doppler carotid screening before surgical (SAVR) or trans-
catheter aortic valve replacement (TAVR) with a balloon-expandable
valve between 1/2007 and 8/2014. Logistic regressionmodelswere used
to determine the relation between 30-day post-procedure stroke and
total (sum of left and right ICAS) and maximal unilateral ICAS. The
model was adjusted for age, gender, history of atrial ﬁbrillation, prior
cerebrovascular disease and diabetes, left ventricular ejection fraction,
and procedure type. 11 patients who underwent carotid intervention
before valve replacementwere excluded from the logisticmodels. Two-
subgroup analyses were performed in patients that underwent TAVR
and SAVR further adjusting for procedure speciﬁc details.
RESULTS 991 patients underwent ICAS screening prior to TAVR
(n¼467) or SAVR (n¼529). In the entire group, the prevalence of 70%
asymptomatic ICAS was 4.9% (n¼49) and incidence of 30-day stroke
was 3.4% (n¼34). We did not ﬁnd an association between stroke and
either the total or maximal unilateral ICAS in our adjusted analysis for
all patients (p¼0.09 and p¼0.31). There was no difference between
those patients that underwent TAVR (p¼0.15 and 0¼0.44) or SAVR
(p¼0.30 and p¼0.49, Figure 1)
CONCLUSIONS The incidence of signiﬁcant ICAS in preoperative
screening for TAVR or SAVR is uncommon. Our study suggests that
ICAS plays little or no role in the occurrence of procedure-related
stroke after aortic valve replacement. Arguing against routine carotid
Doppler screening before isolated TAVR or SAVR.
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BACKGROUND Moderate or severe aortic regurgitation (AR) in pa-
tients with severe aortic stenosis (AS) undergoing transcatheter aortic
valve replacement (TAVR) may adversely impact clinical outcomes.
One of the modalities used to reduce residual AR is to implant a sec-
ond device in the same procedure. This study details the results and
outcome of patients who underwent a second CoreValve (CV) im-
plantation to treat residual AR following the initial CV placement.
METHODS Patients with severe AS treated with CV device who had mod-
erate or severe AR underwent optimized balloon sizing post dilation but
continued to have signiﬁcant residual AR post BAV and were subjected to a
